Atlas Venture Fund X L.P. 13D and 13G filings for Magenta Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-05-05 4:01 pm Sale | 2021-04-13 | 13D | Magenta Therapeutics, Inc. MGTA | Atlas Venture Fund X L.P. | 2,977,448 5.100% | -379,892 (-11.32%) | Filing |
| 2021-02-17 08:26 am Sale | 2021-02-11 | 13D | Magenta Therapeutics, Inc. MGTA | Atlas Venture Fund X L.P. | 3,357,340 7.000% | -759,785 (-18.45%) | Filing |
| 2020-07-14 4:34 pm Unchanged | 2020-06-29 | 13D | Magenta Therapeutics, Inc. MGTA | Atlas Venture Fund X L.P. | 4,117,125 8.700% | 0 (Unchanged) | Filing |